New technique paves way for better drugs

Image
Press Trust of India London
Last Updated : Jul 06 2013 | 12:20 PM IST
Swedish scientists have developed a technique to directly measure the extent to which drugs reach their targets in the cell.
The method, developed by researchers at Karolinska Institutet, could make a significant contribution to the development of new, improved drug substances.
Most drugs operate by binding to one or more proteins and affecting their function, which creates two common bottlenecks in the development of drugs; identifying the right target proteins and designing drug molecules able to efficiently seek out and bind to them.
No method has been available for directly measuring the efficiency of the drug molecules to locate and bind to its target protein.
Now researchers have developed a new tool called CETSA (Cellular Thermal Shift Assay), which utilise the concept that target proteins usually get stabilised when drug molecules bind.
"We have shown that the method works on a wide variety of target proteins and allows us to directly measure whether the drug molecules reach their targets in cells and animal models," said lead investigator Professor Par Nordlund of the Department of Medical Biochemistry and Biophysics.
"We believe that CETSA will eventually help to improve the efficiency of many drugs and contribute to better drug molecules and more successful treatments," Nordlund said.
The lack of methods to directly measure the binding of a drug to its target protein has caused a degree of uncertainty in many phases of drug development.
In some cases, where drug candidates have not lived up to expectations in clinical trials on humans, it has transpired that the drug molecules have failed to bind to the right protein.
The group behind the study believes that CETSA will be an important control stage and a complement to other methods.
In the present study, the researchers also examined processes that can lead to drug resistance in cells.
The team believes that by virtue of its ability to determine whether existing drugs are suitable for individual patients, the method is of potential value to the practice of individualised treatment.
The study was published in the journal Science.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 06 2013 | 12:20 PM IST

Next Story